Pediatric Nephrology

, Volume 19, Issue 1, pp 51–56 | Cite as

Henoch-Schönlein purpura nephritis: course of disease and efficacy of cyclophosphamide

  • Penina TarshishEmail author
  • Jay Bernstein
  • Chester M. EdelmannJr
Original Article


Nephritis in Henoch-Schönlein purpura (HSP) is the primary cause of morbidity and mortality. Although many therapeutic regimens have been reported to be effective, no therapy has been shown in a controlled trial to be beneficial. Fifty-six patients with histopathologically severe HSP nephritis were randomized to receive supportive therapy with or without cyclophosphamide, 90 mg/m2/day for 42 days. Patients were classified according to status at final follow-up: Fully Recovered 48.2%, Persistent Abnormalities 39.3%, or ESRD/Death 12.5%. There were no differences in onset data or outcome between the two trial groups or in outcome between trial and 23 non-trial patients followed concurrently. Therefore, data from trial and non-trial patients were combined for further analysis. There was no correlation between outcome and age, blood pressure, serum total protein, or serum albumin. Although rates of proteinuria did not correlate with outcome, all those with progression to ESRD had nephrotic levels of proteinuria at onset. Only five of 28 patients with nephrotic levels of proteinuria and severe onset histopathology recovered fully. No patient with crescents in 50% or more of glomeruli went on to full recovery. Recurrence of non-renal symptoms did not correlate with outcome. Nephrotic syndrome, decreased GFR, and more severe histopathology at onset, as well as persistence of urinary abnormalities for several years, are ominous signs.


Purpura Henoch-Schönlein Cyclophosphamide Nephritis Natural history Pediatrics Clinical trial 



Work performed: Albert Einstein College of Medicine. Financial support by National Institutes of Health Research Grant 1-RO1-AM18234, the National Kidney Foundation of New York, the Kidney Disease Institute of the State of New York, the William Beaumont Hospital Pathology Projects Fund, the John Rath Foundation, the National Kidney Research Foundation (United Kingdom), and the Kidney Foundation of the Netherlands. Participants in the ISKDC who contributed to this study were as follows: Central Office (New York): H.L. Barnett and C.M. Edelmann Jr. (Directors), I. Greifer (Associate Director), D.I. Goldsmith and A. Spitzer (Directors of Coordinating Center), P. Tarshish (Data Coordinator), G. Laddomada (Project Administrator), and J. Massaro (Secretarial Assistant); Regional Coordinators: I.B. Houston, R.H. Kuijten, and L.B. Travis; Directors of Participating Centers: R.H.R. White (Birmingham, Alabama), I.B. Houston (Manchester, United Kingdom), J.G. Mongeau (Montreal, Canada), N. Hallman and J. Vilska (Helsinki), S.R. Meadow (Leeds, United Kingdom), M.J. Schoeneman and R. Weiss (New York-Albert Einstein), S. Roy (Memphis, Tennessee), G. Gordillo (Mexico City, Mexico), J. Lewy (New York-New York Hospital), O. Oetliker (Bern, Switzerland), Bowman Gray Hospital (North Carolina, USA), M. Nash (New York-Columbia Presbyterian), M. McVicar (North Shore University Hospital-New York), A. Fanconi (Zurich, Switzerland); Consultants: J. Bernstein, J. Churg, R. Habib, and R.H.R. White (Pathology) and S.M. Wassertheil-Smoller (Biostatistics).


  1. 1.
    Austin HA, Balow JE (1983) Henoch-Schönlein nephritis: prognostic features and the challenge of therapy. Am J Kidney Dis 2:512–520PubMedGoogle Scholar
  2. 2.
    Wedgewood RJP, Klaus MH (1955) Anaphylactoid purpura. A long-term follow-up study with special reference to renal involvement. Pediatrics 16:196–206PubMedGoogle Scholar
  3. 3.
    Levy M, Broyer M, Arsan A, Levy-Bentolila D, Habib R (1976) Anaphylactoid purpura nephritis in childhood: natural history and immunopathology. Adv Nephrol 6:183–224PubMedGoogle Scholar
  4. 4.
    Meadow SR, Glasgow EF, White RHR, Moncrieff MW, Cameron JS, Ogg CS (1972) Schönlein-Henoch nephritis. Q J Med 163:241–258Google Scholar
  5. 5.
    Hurley RM, Drummond KN (1972) Anaphylactoid purpura nephritis: clinicopathological correlations. J Pediatr 81:904–911PubMedGoogle Scholar
  6. 6.
    Allen DM, Diamond LK, Howell DA (1960) Anaphylactoid purpura in children. Am J Dis Child 99:833–854Google Scholar
  7. 7.
    Ostergaard JR, Storm K (1991) Neurologic manifestations of Schönlein-Henoch purpura. Act Pediatr Scand 80:339–342Google Scholar
  8. 8.
    Stewart M, Savage JM, Bell B, McCord B (1988) Long term renal prognosis of Henoch-Schönlein purpura in an unselected childhood population. Eur J Pediatr 147:113–115PubMedGoogle Scholar
  9. 9.
    Mollica F, Li Volti S, Garozzo R, Russo G (1992) Effectiveness of early prednisone treatment in preventing the development of nephropathy in anaphylactoid purpura. Eur J Pediatr 151:140–144PubMedGoogle Scholar
  10. 10.
    Sterky G, Thilen A (1960) Study on the onset and prognosis of acute vascular purpura (the Schönlein Henoch syndrome) in children. Act Pediatr 49:217–229Google Scholar
  11. 11.
    Vernier RL, Worthen HG, Peterson RD, Colle E, Good RA (1961) Anaphylactoid purpura. Pathology of the skin and kidney and frequency of streptococcal infection. Pediatrics 27:181–193Google Scholar
  12. 12.
    Ronkainen J, Nuutinen M, Koskimies O (2002) The adult kidney 24 years after childhood Henoch-Schönlein purpura: a retrospective cohort study. Lancet 360:666–670CrossRefPubMedGoogle Scholar
  13. 13.
    Scharer K, Krmar R, Querfeld U, Ruder H, Waldherr R, Schaefer F (1999) Clinical outcome of Schönlein-Henoch purpura nephritis in children. Pediatr Nephrol 13:816–823CrossRefPubMedGoogle Scholar
  14. 14.
    Schwartz GJ, Brion LP, Spitzer A (1987) The use of plasma creatinine concentration for estimating glomerular filtration rate in infants, children, and adolescents. Pediatr Clin North Am 34:571–590PubMedGoogle Scholar
  15. 15.
    Tejani A (2001) Personal communication. NAPRTCS dataGoogle Scholar
  16. 16.
    Loirat C, Ehrich JHH, Geerlings W, Jones EHP, Landais P, Mallick NP, Margreiter R, Raine AEG, Salmela K, Selwood NH, Tufveson G, Valderrabano F (1994) Report on management of renal failure in children in Europe, XXIII, 1992. Nephrol Dial Transplant Suppl 1:26–40Google Scholar
  17. 17.
    Tanaka H, Suzuki K, Nakahata T, Ito E, Waga S (2003) Early treatment with oral immunosuppressants in severe proteinuric purpura nephritis. Pediatr Nephrol 18:347–350Google Scholar
  18. 18.
    Meadow SR (1978) The prognosis of Henoch Schönlein nephritis. Clin Nephrol 9:87–90PubMedGoogle Scholar
  19. 19.
    Rai A, Nast C, Adler S (1999) Henoch-Schönlein purpura nephritis. J Am Soc Nephrol 10:2637–2644PubMedGoogle Scholar
  20. 20.
    Flynn JT, Smoyer WE, Bunchman TE, Kershaw DB, Sedman AB (2001) Treatment of Henoch-Schönlein purpura glomerulonephritis in children with high dose corticosteroids plus oral cyclophosphamide. Am J Nephrol 21:128–133CrossRefPubMedGoogle Scholar
  21. 21.
    Niaudet P, Habib R (1998) Methylprednisolone pulse therapy in the treatment of severe forms of Schönlein-Henoch purpura nephritis. Pediatr Nephrol 12:238–243CrossRefPubMedGoogle Scholar
  22. 22.
    Kaku Y, Nohara K, Honda S (1998) Renal involvement in Henoch-Schönlein purpura: a multivariate analysis of prognostic factors. Kidney Int 53:1755–1759PubMedGoogle Scholar
  23. 23.
    Szer IS (1996) Henoch-Schönlein purpura: when and how to treat. J Rheum 23:1661–1665PubMedGoogle Scholar
  24. 24.
    Iijima K, Ito-Kariya S, Nakamura H, Yoshikawa N (1998) Multiple combined therapy for severe Henoch-Schönlein nephritis in children. Pediatr Nephrol 12:244–248CrossRefPubMedGoogle Scholar
  25. 25.
    Counahan R, Winterborn MH, White RHR, Heaton JM, Meadow SR, Bluett NH, Swetschin H, Cameron JS, Chantler C (1977) Prognosis of Henoch-Schönlein nephritis in children. BMJ 2:11–14PubMedGoogle Scholar
  26. 26.
    Koskimies O, Mir S, Rapola J, Vilska J (1981) Henoch-Schönlein nephritis: long term prognosis of unselected patients. Arch Dis Child 56:482–483PubMedGoogle Scholar
  27. 27.
    Yoshikawa N, White RHR, Cameron AH (1981) Prognostic significance of the glomerular changes in Henoch-Schoenlein nephritis. Clin Nephrol 16:223–229Google Scholar
  28. 28.
    Bircan Z, Katar S, Batum S, Yilmaz AY, Comert S, Vitrinel A (2000) Prognosis of Henoch-Schönlein nephritis in children (abstract). Pediatr Nephrol 14:C70Google Scholar
  29. 29.
    Goldstein AR, Akuse R, White RHR, Chantler C (1992) Long-term follow-up of childhood Henoch-Schönlein nephritis. Lancet 339:280–282PubMedGoogle Scholar

Copyright information

© IPNA 2003

Authors and Affiliations

  • Penina Tarshish
    • 1
    • 3
    Email author
  • Jay Bernstein
    • 2
  • Chester M. EdelmannJr
    • 1
  1. 1.Albert Einstein College of MedicineNew YorkUSA
  2. 2.Department of Anatomic PathologyWilliam Beaumont HospitalRoyal OakUSA
  3. 3.Room 803Jacobi Medical CenterBronxUSA

Personalised recommendations